CES 2025 is one of the world’s largest technology exhibitions. It brings together innovators, industry leaders, and visionaries from around the globe. This year, Orange Biomed proudly showcased our cutting-edge OBM rapid A1c device.
The OBM rapid A1c is the world’s first microfluidics-based A1c measurement tool. It is designed to make diabetes management more accessible and accurate for all. This innovation reflects Orange Biomed’s commitment to advancing healthcare technology.
Our participation at CES 2025 was more than just a product showcase. It was an opportunity to shape the future of diabetes care. Through meaningful connections and strategic engagements, Orange Biomed demonstrated our leadership in the field.
Orange Biomed's First Day at the Consumer Electronics Show
K-Startup Night Highlights
Orange Biomed Manager Youra Park led a presentation on our breakthrough technology application during the K-Startup Night event, which brought together industry leaders and innovators. Park detailed how our A1C analysis device uses advanced microfluidic technology and a micro-electro-mechanical system (MEMS) to perform single-cell analysis of red blood cells, delivering rapid, lab-accurate results from a minimal blood sample.
The event proved to be a valuable networking opportunity, resulting in meaningful connections:
- Sergiy Montano: Vice President of Marketing at Zhittya Genesis Medicine, demonstrated a strong understanding of HbA1c testing and introduced the team to other key figures, such as John Laub.
- Anahit Baghshetsyan: Co-founder of Toon, engaged in discussions about potential collaborations and highlighted her experience working with startups.
- John Laub: CEO of WUND Healing Biopharmaceuticals, shared insights into startup fundraising and biopharmaceutical innovations. His keynote speech underscored his expertise and leadership in the industry.
These interactions set the tone for future collaborations, and the connections made during the event paved the way for continued engagement throughout CES.
Visitor Engagements
Alongside Youra Park, production team member Sangwoo Kim allowed attendees to demo OBM rapid A1c before its release. Orange Biomed’s booth witnessed a quieter start compared to other major events like MEDICA, but the team capitalized on this by holding in-depth conversations with key visitors:
- 1. HOSPI Research Team:
Expressed interest in portable HbA1c measurement and highlighted the importance of accuracy and reliability in diagnostic tools.
- 2. Zero Doctors:
CEO Young-hoon Son, who leads a large network of diabetes clinics in Korea, suggested adding C-peptide measurement and explored opportunities for market distribution.
- 3. KISED Representative:
Hyeok-kyung Kwon provided recommendations for business matches and suggested visiting other exhibitors like CorPal Health and Biopop.
Additionally, Digital Healthcare Partners (DHP), one of Orange Biomed’s key investors, facilitated introductions to other influential figures, further strengthening the company’s industry ties.
Day 2: Strengthening Ties and Expanding Opportunities
Key Revisits
The second day saw several key visitors returning for in-depth discussions.
- John Laub, a prominent investor and industry leader, revisited the booth to gain more insights into the OBM rapid A1c device and its potential impact.
- Carl Wong, CEO of Infinio Capital, expressed enthusiasm for the product and highlighted the importance of network functionality for home-use A1c meters. He also introduced Jerry Nakafuji, Managing Director at AiTmed, opening new avenues for collaboration.
Support from Partners
Orange Biomed also received visits from critical investors:
- Haejoon (Harry) Jung from KSC Seattle offered insights and support, reflecting investor confidence in the product.
- Cheolmin Yoon from INTOPS one of Orange Biomed’s key investors, discussed strategies to drive growth and innovation further.
New Connections
Day 2 facilitated new and promising relationships:
- The team had productive discussions with representatives from Apollon, a company focusing on non-invasive continuous glucose monitoring. Apollon is preparing for FDA approval and large-scale clinical trials, indicating potential synergies with Orange Biomed’s goals.
- Visitors like Bergur Gardar Sandholt from Iceland and Chohay Mun from Seoul National University were particularly impressed with the OBM rapid A1c device. Bergur noted the device’s portability and accuracy, while Chohay emphasized its calibration-free functionality and its potential to rival benchtop devices.
Day 3: Insights and Innovations From the Consumer Electronics Show
Exploring Other Booths
The final day at CES 2025 provided Orange Biomed the opportunity to gather valuable insights from other exhibitors.
- Sky Labs: The team visited Sky Labs to learn about their innovative ring-shaped device for continuous blood pressure monitoring. This device has already achieved reimbursement approval in 1,200 hospitals, thanks to its seamless integration with existing hospital systems and cloud storage for personal use.
- Laser Blood Sampling Companies: Companies like LaMeditech and MVITRO showcased their laser-based devices for glucose and hemoglobin monitoring. Lameditech’s FDA-approved technology highlighted the potential of needle-free sampling for personal use.
- CorPal Health: This Turkish startup demonstrated their impressive AI-driven app for chronic disease management and rehabilitation therapy. Their B2B approach targets hospitals and insurance companies, providing tailored, real-time guidance for patients.
Valuable Feedback
The Orange Biomed booth continued to attract visitors, offering constructive insights:
- Younghan Kang from SK Japan Investment commended the OBM rapid A1c device while suggesting adjustments to the pricing model for broader market appeal.
- Chohay Mun, an adjunct professor at Seoul National University, praised the device’s accuracy and its calibration-free design, comparing it favorably to traditional benchtop models.
- Jae-young Kim, a medical interpreter, shared personal experiences with prediabetes diagnosis, emphasizing the need for reliable A1c measurements in smaller clinics.
Microfluidic Technology at CES
Orange Biomed made a significant impact at CES 2025 with our innovative OBM rapid A1c device, the world’s first microfluidics-based A1C measurement tool. This technology application demonstrated our leadership in precision diagnostics and commitment to improving diabetes care through accessible and accurate solutions.
Orange Biomed’s Contributions
The OBM rapid A1c device stood out as a pioneering application of microfluidic technology in healthcare. It combines accuracy with portability, setting a benchmark in diabetes management. The device not only captured the interest of visitors, further solidifying Orange Biomed’s reputation as a trailblazer in microfluidics.
Other Microfluidics Exhibitors
Orange Biomed was not alone in showcasing microfluidic innovation. Key ecosystem players and exhibitors at CES 2025 included:
- O-in: Featured gravity-driven microfluidic systems, primarily adopted in the veterinary market.
- Solventum: Formerly known as 3M Health Care, Solventum presented advanced medical technologies utilizing microfluidics.
- TheDABOM Inc: Focused on creating artificial exosomes using microfluidic technology for precise applications. They also presented at the Seoul Pavilion Stage IR Pitching.
Significance of Microfluidics at CES
Microfluidic technology was a central theme at CES, illustrating its growing role in reshaping diagnostics and healthcare. Orange Biomed’s presence alongside other innovators emphasized the potential of this technology to deliver game-changing solutions in diverse fields.
Key Takeaways and Future Prospects from CES
Looking Ahead
Orange Biomed is ready to act on insights from CES 2025. We plan to expand our global reach and build new partnerships. Future innovations will focus on advancing microfluidic diagnostics. Lessons from CES will shape our approach to upcoming events and expos.
Orange Biomed’s participation at CES 2025 was a resounding success. The OBM rapid A1c device captured the attention of industry leaders, investors, and innovators. It demonstrated the company’s commitment to advancing diabetes care through cutting-edge technology.
Meaningful collaborations and valuable insights gained at CES will drive our future innovations. Our vision to transform healthcare remains clear and unwavering.
Orange Biomed is poised to shape the future of diabetes care. With our pioneering approach and dedication to excellence, we are ready to make a lasting global impact.
FAQs
1. What is the Consumer Electronics Show?
The Consumer Electronics Show (CES) is the world’s largest technology trade show, showcasing innovations in consumer electronics, healthcare, AI, automotive, and more. It is held annually in Las Vegas and attracts companies, industry leaders, and tech enthusiasts from around the globe.
2. Can anyone go to the Consumer Electronics Show?
No, CES is not open to the general public. It is an industry-only event for professionals, including exhibitors, buyers, media, and other stakeholders in the technology and electronics sectors. Attendees must be at least 18 years old and have credentials to register.
3. Is CES a big deal?
Yes, CES is a major event in the tech industry. It serves as a global platform for companies to launch new products, demonstrate cutting-edge technologies, and network with industry leaders. The event sets trends and shapes the future of technology.
4. How much does it cost to attend CES?
The cost to attend CES depends on the type of registration. Basic registration starts at around $300, while premium passes for exclusive sessions and events can cost several thousand dollars. Additional travel and accommodation costs also apply.
5. Is CES still called the Consumer Electronics Show?
While CES originally stood for Consumer Electronics Show, the organizers now simply refer to it as CES. This reflects the event’s broader focus on various industries beyond consumer electronics, such as healthcare, automotive, and sustainability.
